How to take methylene blue: what do the sources say?

Forms and strengths on the labels
ProductStrengthLabel direction
Provayblue injection110 mg/2 mL and 50 mg/10 mL, both 5 mg/mL1 mg/kg intravenously over 5-30 minutes
Ozipco solution, sold as a dietary supplement61%, 59.2 ml bottleMix 1 ml (20 drops) with 200 ml of water, or use according to established research protocols; for adult use only
Uro-MP, combination product210 mg per unitAdults: one tablet orally 4 times per day followed by liberal fluid intake
Uribel, combination product310.8 mg per tabletAdults: one tablet orally 4 times per day followed by liberal fluid intake

The Provayblue label gives 1 mg/kg intravenously over 5-30 minutes for acquired methemoglobinemia, two urinary combination product labels indicated for symptoms of irritative voiding give adults one tablet orally 4 times per day, and single-dose trials gave oral doses of 150 to 500 mg.12345

Forms and strengths on the labels

The table is set at the top of the page

The pack's DailyMed search found only these four labels, and no label giving strengths of oral methylene blue supplement capsules.623

Route, approval and warnings

The Provayblue label indicates the injection for pediatric and adult patients with acquired methemoglobinemia, gives the dose intravenously and says not to give it subcutaneously.1 The label gives an initial U.S. approval of 2016 for the injection, and the TGA says methylene blue products are only prescription-only when presented for injection.17 It carries a boxed warning on serotonin syndrome with serotonergic drugs and opioids, and it contraindicates use in G6PD deficiency.1 Australia's TGA says unregistered oral methylene blue products in Australia have not been assessed for quality, safety or efficacy, advises against using them unless advised or prescribed by a healthcare professional, and names serious risks including serotonin syndrome, birth defects and haemolysis.7

Doses on the label and in trials

The Provayblue label allows a repeat of up to 1 mg/kg one hour later if methemoglobin stays above 30% or symptoms persist.1 The label puts the maximum number of doses at two, and gives a single dose of 1 mg/kg in moderate or severe renal impairment (eGFR 15-59 mL/min/1.73 m2).1 The pack's PubMed and ClinicalTrials.gov searches found no human trial of repeated oral low-dose methylene blue for wellness; the methylene blue trials below gave single doses.

TrialDose and schedulePeopleLength
Walter-Sack et al., 2009, phase I5500 mg oral aqueous and 50 mg intravenous; then chloroquine 750 mg oral alone or with 500 mg oral16 healthy peopleSingle doses, 1-week wash-out, then a second week
Repici et al., 2012, MMX tablets8200 mg or 400 mg oral; 200 mg also compared with 100 mg intravenous, after 2 L of bowel cleansing preparation22 healthy volunteersSingle dose
Colon Staining Efficacy of Single Oral Doses of Methylene Blue MMX (NCT03287219), open-label registry record, started 20114Six or eight 25 mg MMX tablets (150 or 200 mg), oral, with a 4-L PEG-based bowel cleansing preparation114 patients undergoing a full colonoscopySingle dose
Rodriguez et al., 20169Low-dose oral methylene blue or placeboTwenty-six subjects aged 22–62 yearsImaging before and 1 hour after dosing
Wilcock et al., LMTM trial10100 mg or 4 mg twice a day, oral tablets800 people with mild Alzheimer'sUp to 78 weeks
LUCIDITY, Wischik et al.11Hydromethylthionine mesylate 16 mg/day, 8 mg/day or placebo, 4:1:4545 patients with probable AD or MCI-ADDouble-blind phase, then open-label 16 mg/day

The last two rows test LMTM, which its authors say stabilizes the reduced form of the MT moiety in the solid state,10 and hydromethylthionine mesylate,11 forms that differ from methylene blue chloride and whose doses are not interchangeable with it. The authors of the LMTM paper note an earlier phase 2 trial in which methylthioninium chloride at 138 mg/day produced a significant treatment effect on the ADAS-cog at 24 weeks compared with placebo.10 The pack's searches found no brain health, performance or cycling label or trial. Milligram has no logged methylene blue figure to report.

Mixing, dilution and storage

The Provayblue label says the injection may be diluted in 50 mL of 5% Dextrose Injection to avoid local pain, particularly in the pediatric population, and the diluted solution used immediately.1 The pack's searches found no label or trial naming a water or volume for an oral powder, and none gives a U-100 syringe mark.

The Provayblue label gives storage at 20°C to 25°C with excursions to 15°C to 30°C, no refrigeration or freezing, and the original package to protect from light.1 The pack's searches found no stability data for home-mixed solutions.

Frequently asked questions

How much of an oral dose of methylene blue is absorbed?

In Walter-Sack et al.'s 2009 phase I study of 16 healthy people, absolute bioavailability of a single 500 mg aqueous oral dose was 72.3 +/- 23.9%.5 In Repici et al.'s 2012 study of 22 healthy volunteers, 200 mg MMX tablets taken after 2 L of bowel cleansing preparation peaked at a median of 16 h, with average absolute bioavailability of 139.19 ± 52.00% against 100 mg intravenous.8 The two figures come from an aqueous oral dose and from MMX tablets taken with a bowel cleansing preparation.

References

  1. American Regent (DailyMed). These highlights do not include all the information needed to use (PROVAYBLUE) safely and effectively. See full prescribing information for (PROVAYBLUE). PROVAYBLUE ® (methylene blue) injection, USP for intravenous use Initial U.S. Approval: 2016. 2025. dailymed.nlm.nih.gov
  2. DailyMed. URO-MP Capsules. 2025. dailymed.nlm.nih.gov
  3. DailyMed. Uribel Tabs. 2026. dailymed.nlm.nih.gov
  4. ClinicalTrials.gov. NCT03287219: Colon Staining Efficacy of Single Oral Doses of Methylene Blue MMX. 2021. clinicaltrials.gov
  5. PubMed. High absolute bioavailability of methylene blue given as an aqueous oral formulation. 2009. pubmed.ncbi.nlm.nih.gov
  6. DailyMed. DIRECTIONS. 2026. dailymed.nlm.nih.gov
  7. Therapeutic Goods Administration (Australia). Imported unregistered methylene blue products. tga.gov.au
  8. PubMed. Methylene blue MMX tablets for chromoendoscopy. Safety tolerability and bioavailability in healthy volunteers. 2012. pubmed.ncbi.nlm.nih.gov
  9. PMC. Multimodal Randomized Functional MR Imaging of the Effects of Methylene Blue in the Human Brain. pmc.ncbi.nlm.nih.gov
  10. PMC. Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer’s Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial. 2017. pmc.ncbi.nlm.nih.gov
  11. PMC. Oral Tau Aggregation Inhibitor for Alzheimer’s Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate. 2022. pmc.ncbi.nlm.nih.gov